CADTH Canadian Drug Expert Committee recommendation. indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) :
The CADTH Canadian Drug Expert Committee (CDEC) recommends that ocrelizumab be reimbursed for the treatment of relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical and imaging features.
Saved in:
Online Access: |
http://www.ncbi.nlm.nih.gov/books/NBK534395/ Full text |
---|---|
Corporate Author: | |
Format: | Electronic eBook |
Language: | English |
Published: |
Ottawa (ON) :
Canadian Agency for Drugs and Technologies in Health,
2017
|
Edition: | Version 1.0. |
Series: | Common drug review clinical review report.
|
Subjects: |